Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy

American Journal of Neuroradiology

Volumn 33, Issue 8, 2012, Pages 1596-1601

  Hagemeier, J ^a   Weinstock Guttman, B ^b   Bergsland, N ^a   Heininen Brown, M ^a   Carl, E ^a   Kennedy, C ^a   Magnano, C ^a   Hojnacki, D ^b   Dwyer, M G ^a   Zivadinov, Robert ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE DURATION; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; MALE; MEAN PHASE OF THE ABNORMAL PHASE TISSUE; NORMAL PHASE TISSUE VOLUME; NUCLEAR MAGNETIC RESONANCE IMAGING; PULVINAR; PUTAMEN; SUBCORTICAL DEEP GRAY MATTER; SUBSTANTIA NIGRA; SUSCEPTIBILITY WEIGHTED IMAGING; SYNDROME; WHITE MATTER;

ADULT; ATROPHY; BRAIN; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IRON; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE;

EID: 84866350738     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3030     Document Type: Article

References (54)

1. Pirko I, Lucchinetti CF, Sriram S, et al. Gray matter involvement in multiple sclerosis. Neurology 2007;68:634-42 (Pubitemid 46667808)
2. Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255-65
3. Audoin B, Ibarrola D, Malikova I, et al. Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis-a two-year longitudinal MRI/MRSI study of corpus callosum. Mult Scler 2007;13:41-51 (Pubitemid 46152760)
4. Audoin B, Zaaraoui W, Reuter F, et al. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:690-95
5. Calabrese M, Atzori M, Bernardi V, et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007;254:1212-20 (Pubitemid 350112349)
6. Henry RG, Shieh M, Amirbekian B, et al. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009;282:61-66
7. Henry RG, Shieh M, Okuda DT, et al. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79:1236-44
8. Ramasamy DP, Benedict RH, Cox JL, et al. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci 2009;282:47-54
9. Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011;17:1098-106
10. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64:247-54
11. Calabrese M, Rinaldi F, Mattisi I, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77:257-63
12. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101-07 (Pubitemid 38623045)
13. Raz E, Cercignani M, Sbardella E, et al. Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Radiology 2010;257:448-54
14. Bakshi R, Benedict RHB, Bermel RA, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002;59:62
15. Brass SD, Benedict RHB, Weinstock-Guttman B, et al. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 2006;12:437
16. Tjoa CW, Benedict RH, Weinstock-Guttman B, et al. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 2005;234:17-24 (Pubitemid 40910338)
17. Burgetova A, Seidl Z, Krasensky J, et al. Multiple sclerosis and the accumulation of iron in the basal ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry. Eur Neurol 2010;63:136-43
18. Khalil M, Enzinger C, Langkammer C, et al. Quantitative assessment of brain iron by R(2)*relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009;15:1048-54
19. Khalil M, Langkammer C, Ropele S, et al. Determinants of brain iron in multiple sclerosis: A quantitative 3T MRI study. Neurology 2011;77:1691-97
20. Ge Y, Jensen JH, Lu H, et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007;28:1639
21. Eissa A, Lebel RM, Korzan JR, et al. Detecting lesions in multiple sclerosis at 4.7 Tesla using phase susceptibility-weighting and T2-weighting. J Magn Reson Imaging 2009;30:737-42
22. Haacke EM, Makki M, Ge Y, et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009;29:537-44
23. Zivadinov R, Heininen-Brown M, Schirda C, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis. A case-control study. Neuroimage 2012;59:331-39
24. Craelius W, Migdal MW, Luessenhop CP, et al. Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 1982;106:397-99
25. LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 1997;760:298-303
26. Fenton H.J.H. Oxidation of tartaric acid in presence of iron. J Chem Soc 1894;65:899-903
27. Khalil M, Teunissen C, and Langkammer C. Iron and neurodegeneration in multiple sclerosis. Mult Scler Int 2011:606807
28. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-88 (Pubitemid 40545039)
29. Ceccarelli A, Rocca MA, Neema M, et al. Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 2010;16:39-44
30. Neema M, Arora A, Healy BC, et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009;19:3-8
31. Haacke EM, Mittal S, Wu Z, et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009;30:19
32. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
33. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52 (Pubitemid 14237132)
34. Patenaude B, Smith SM, Kennedy DN, et al. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907-22
35. Batista S, Zivadinov R, Hoogs M, et al. Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 2012;259:139-46
36. Yeh EA, Weinstock-Guttman B, Ramanathan M, et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain 2009;132:3392-400
37. Zivadinov R, Weinstock-Guttman B, Benedict R, et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet 2007;16:2659-68 (Pubitemid 350018508)
38. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-47 (Pubitemid 32947383)
39. Bakshi R, Shaikh ZA, Janardhan V. MRIT2 shortening ("black T2") in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 2000;11:15-21 (Pubitemid 30053382)
40. Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707-13
41. Drayer B, Burger P, Darwin R, et al. MRI of brain iron. AJR Am J Roentgenol 1986;147:103-10 (Pubitemid 16066336)
42. Bakshi R, Dmochowski J, Shaikh ZA, et al. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 2001;185:19-26 (Pubitemid 32215497)
43. Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005;62:1371-76 (Pubitemid 41352053)
44. Ceccarelli A, Filippi M, Neema M, et al. T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler 2009;15:678-86
45. Ceccarelli A, Rocca MA, Perego E, et al. Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. Mult Scler 2011;17:702-07
46. Hopp K, Popescu BF, McCrea RP, et al. Brain iron detected by SWI high pass filtered phase calibrated with synchrotron X-ray fluorescence. J Magn Reson Iimaging 2010;31:1346-54
47. Haacke EM, Xu Y, Cheng YC, et al. Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612-18 (Pubitemid 39108975)
48. Stankiewicz J, Panter SS, Neema M, et al. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007;4:371-86 (Pubitemid 46962416)
49. Snyder AM, Connor JR. Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 2009;1790:606-14
50. Haacke EM, Garbern J, Miao Y, et al. Iron stores and cerebral veins in MS studied by susceptibility weighted imaging. Int Angiol 2010;29:149-57
51. Zivadinov R, Weinstock-Guttman B, Pirko I. Iron deposition and inflammation in multiple sclerosis. Which one comes first? BMC Neurosci 2011;12:60
52. Williams R, Rohr AM, Wang WT, et al. Iron deposition is independent of cellular inflammation in a cerebral model of multiple sclerosis. BMC Neurosci 2011;12:59
53. Schweser F, Deistung A, Lehr BW, et al. Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: An approach to in vivo brain iron metabolism? Neuroimage 2011;54:2789-807
54. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97